Compare SCL & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCL | NEO |
|---|---|---|
| Founded | 1932 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1994 | 2008 |
| Metric | SCL | NEO |
|---|---|---|
| Price | $50.46 | $9.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $75.00 | $11.14 |
| AVG Volume (30 Days) | 167.1K | ★ 1.8M |
| Earning Date | 05-27-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | ★ 25.71 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $1,803,737,000.00 | N/A |
| Revenue This Year | $8.79 | $10.53 |
| Revenue Next Year | $8.14 | $9.25 |
| P/E Ratio | $27.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $41.82 | $4.72 |
| 52 Week High | $68.00 | $13.74 |
| Indicator | SCL | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 32.48 | 31.59 |
| Support Level | $47.21 | $9.13 |
| Resistance Level | $51.10 | $11.02 |
| Average True Range (ATR) | 2.46 | 0.61 |
| MACD | -2.19 | -0.14 |
| Stochastic Oscillator | 8.76 | 26.35 |
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.